LG's new diabetes drug to begin global sales
21-Jan-16, Business Korea
LG Life Sciences, the biopharmaceuticals unit of the LG Group, will start selling the nation’s first diabetes treatment Zemiglo in the global market in earnest.
%20LG_Business%20Korea.png "LGs new diabetes drug to begin global sales (c) LG Business Korea")
Image: LG / Business Korea
In a bid to tap into the global market, the Korean drugmaker sealed a licensing partnership with French-based pharma giant Sanofi and Mexico’s Stendhal from 2013 to distribute and market the new diabetes drug in 104 countries globally.
LG Life Sciences was licensed to sell Zemiglo in 9 countries, including India, in 2015. Starting with a launch symposium in Costa Rica, the company will begin releasing and selling the new diabetes treatment in five countries in Central America and India from Mar-16.